ALFA Finder| Management target | Net Profit 25.0% FY27 |
|---|
| Revenue growth | 20% YoY growth; US revenue surged from 14.4Cr to 43.1Cr. |
|---|---|
| Margins | Gross margin at 59.8%; PAT margin at 20.5% target. |
| Order book | US business booked out until February 2027. |
| Demand visibility | Strong; US sterile injectable pipeline has 40+ products pending. |
| Management confidence | Extremely high, focusing on 'turnaround story' and cash-rich balance sheet. |
Growth
Revenue grew 20% YoY, with US markets leading at 187% growth. Gross margins remain high at 59.8%.
Outlook
Expect 55% gross margin and 25% PAT margin. Investing in 17 sterile lines.
Risks
Capacity bottlenecks at CP1 and CSL plants; 1-2 year lead time for new facilities.
Earnings Call Transcript filed with NSE, NSE: CAPLIPOINT. Summary written with AI assistance from the document.
Caplin Point Laboratories Ltd: key numbers
- Share price
- ₹2,557.80
- Market cap
- ₹19,442 Cr
- Revenue (annual)
- ₹2,187 Cr
- Net profit (annual)
- ₹641.2 Cr
- P/E (TTM)
- 29.2×Sector 43.8×
- Promoter holding
- 70.57%+0.00% QoQ
- FII holding
- 5.72%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Caplin Point Laboratories Ltd
All →Caplin Point Laboratories Board Meeting Date
Caplin Point schedules a 12 November 2026 board meeting for unaudited quarterly and half-year results. The trading window stays closed until 14 November 2026.
Caplin Point Laboratories Other Announcement
Caplin Point Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Caplin Point Laboratories Annual General Meeting
Caplin Point Laboratories concluded its 35th Annual General Meeting on September 25, 2026. Key business included adopting financial statements and approving the final dividend declaration.
Caplin Point Laboratories Price Movement Clarification
Caplin Point Laboratories clarified that the recent increase in its stock's trading volume is market-driven. The company confirmed no undisclosed material information exists regarding this movement.
Caplin Point Laboratories Other Announcement
Caplin Point Laboratories Limited shared a weblink for its 35th AGM Notice and Annual Report for FY 2025-26. The communication targets shareholders with unregistered email addresses.
Caplin Point Laboratories Annual General Meeting
Caplin Point Laboratories Limited scheduled its 35th Annual General Meeting for September 25, 2026. Key agenda items include adopting financial statements and declaring a ₹4 final dividend.